FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3167266199> ?p ?o ?g. }

• W3167266199 endingPage "2770" @default.
• W3167266199 startingPage "2770" @default.
• W3167266199 abstract "Platinum-based neoadjuvant chemotherapy (NAC) is widely used for treating muscle-invasive bladder cancer (MIBC). A systematic review was performed following PRISMA guidelines. PubMed, Embase, and the Cochrane Library were searched up to December 2020. We conducted a meta-analysis to compare the oncologic outcomes of ddMVAC (dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin) and GC (gemcitabine and cisplatin), which are the most widely used NAC regimens. Endpoints included pathologic complete response (pCR), pathologic downstaging (pDS), overall survival (OS), and cancer-specific survival (CSS). Five studies, with a total of 1206 patients, were included for meta-analysis. pCR was observed in 35.2% of the ddMVAC arm and in 25.1% of the GC arm, and pCR was significantly higher in ddMVAC than in GC (odds ratio (OR), 1.45; 95% confidence interval (CI), 1.11–1.89; p = 0.006). There was no significant difference in pDS (OR, 1.37; CI, 0.84–2.21; p = 0.20). OS was significantly higher in ddMVAC than in GC (hazard ratio, 2.16; CI, 1.42–3.29; p = 0.0004). Only one study reported CSS outcomes. The results of this analysis indicate that ddMVAC is superior to GC in terms of pCR and OS, suggesting that ddMVAC is more effective than GC in NAC for MIBC. However, this should be interpreted with caution because of the inherent limitations of retrospective studies." @default.
• W3167266199 created "2021-06-22" @default.
• W3167266199 creator A5009511623 @default.
• W3167266199 creator A5024153128 @default.
• W3167266199 creator A5045730291 @default.
• W3167266199 creator A5049287840 @default.
• W3167266199 creator A5077899911 @default.
• W3167266199 creator A5078416571 @default.
• W3167266199 date "2021-06-02" @default.
• W3167266199 modified "2023-09-26" @default.
• W3167266199 title "Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis" @default.
• W3167266199 cites W1588226733 @default.
• W3167266199 cites W1964037817 @default.
• W3167266199 cites W1975918912 @default.
• W3167266199 cites W1992240979 @default.
• W3167266199 cites W2075642745 @default.
• W3167266199 cites W2090241022 @default.
• W3167266199 cites W2098923148 @default.
• W3167266199 cites W2103257412 @default.
• W3167266199 cites W2103561213 @default.
• W3167266199 cites W2103818040 @default.
• W3167266199 cites W2111722073 @default.
• W3167266199 cites W2113156769 @default.
• W3167266199 cites W2116475791 @default.
• W3167266199 cites W2125435699 @default.
• W3167266199 cites W2150849842 @default.
• W3167266199 cites W2160107406 @default.
• W3167266199 cites W2164791945 @default.
• W3167266199 cites W2168846224 @default.
• W3167266199 cites W2332342311 @default.
• W3167266199 cites W2462649057 @default.
• W3167266199 cites W2737911811 @default.
• W3167266199 cites W2768465438 @default.
• W3167266199 cites W2782762180 @default.
• W3167266199 cites W2807188318 @default.
• W3167266199 cites W2887912156 @default.
• W3167266199 cites W2888969259 @default.
• W3167266199 cites W2892310850 @default.
• W3167266199 cites W2946076296 @default.
• W3167266199 cites W2987436342 @default.
• W3167266199 cites W2988581606 @default.
• W3167266199 cites W3008254785 @default.
• W3167266199 cites W3011938621 @default.
• W3167266199 cites W3026086919 @default.
• W3167266199 cites W3081622691 @default.
• W3167266199 cites W3092302767 @default.
• W3167266199 cites W4242669880 @default.
• W3167266199 cites W4294215472 @default.
• W3167266199 cites W884353920 @default.
• W3167266199 doi "https://doi.org/10.3390/cancers13112770" @default.
• W3167266199 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8199668" @default.
• W3167266199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34199565" @default.
• W3167266199 hasPublicationYear "2021" @default.
• W3167266199 type Work @default.
• W3167266199 sameAs 3167266199 @default.
• W3167266199 citedByCount "5" @default.
• W3167266199 countsByYear W31672661992021 @default.
• W3167266199 countsByYear W31672661992022 @default.
• W3167266199 countsByYear W31672661992023 @default.
• W3167266199 crossrefType "journal-article" @default.
• W3167266199 hasAuthorship W3167266199A5009511623 @default.
• W3167266199 hasAuthorship W3167266199A5024153128 @default.
• W3167266199 hasAuthorship W3167266199A5045730291 @default.
• W3167266199 hasAuthorship W3167266199A5049287840 @default.
• W3167266199 hasAuthorship W3167266199A5077899911 @default.
• W3167266199 hasAuthorship W3167266199A5078416571 @default.
• W3167266199 hasBestOaLocation W31672661991 @default.
• W3167266199 hasConcept C121608353 @default.
• W3167266199 hasConcept C126322002 @default.
• W3167266199 hasConcept C126894567 @default.
• W3167266199 hasConcept C143998085 @default.
• W3167266199 hasConcept C156957248 @default.
• W3167266199 hasConcept C207103383 @default.
• W3167266199 hasConcept C2776478404 @default.
• W3167266199 hasConcept C2776694085 @default.
• W3167266199 hasConcept C2777132456 @default.
• W3167266199 hasConcept C2778239845 @default.
• W3167266199 hasConcept C2780258809 @default.
• W3167266199 hasConcept C2780352672 @default.
• W3167266199 hasConcept C2781303535 @default.
• W3167266199 hasConcept C44249647 @default.
• W3167266199 hasConcept C71924100 @default.
• W3167266199 hasConcept C95190672 @default.
• W3167266199 hasConceptScore W3167266199C121608353 @default.
• W3167266199 hasConceptScore W3167266199C126322002 @default.
• W3167266199 hasConceptScore W3167266199C126894567 @default.
• W3167266199 hasConceptScore W3167266199C143998085 @default.
• W3167266199 hasConceptScore W3167266199C156957248 @default.
• W3167266199 hasConceptScore W3167266199C207103383 @default.
• W3167266199 hasConceptScore W3167266199C2776478404 @default.
• W3167266199 hasConceptScore W3167266199C2776694085 @default.
• W3167266199 hasConceptScore W3167266199C2777132456 @default.
• W3167266199 hasConceptScore W3167266199C2778239845 @default.
• W3167266199 hasConceptScore W3167266199C2780258809 @default.
• W3167266199 hasConceptScore W3167266199C2780352672 @default.
• W3167266199 hasConceptScore W3167266199C2781303535 @default.
• W3167266199 hasConceptScore W3167266199C44249647 @default.
• W3167266199 hasConceptScore W3167266199C71924100 @default.

• next